News

General agreement was reached with the FDA on the design and key elements for HTX-011’s Phase 3 program that will be required to support a New Drug Application

Dubbed DEL MAR stage 2, the phase 2b stage 2 clinical trial assessed the performance of Luminate as either a sequential therapy or in combination with anti-VEGF in 80

Tb535H, which is an anti-5T4 pan-cancer T-cell engager, will get support from the Cancer Research UK in its early clinical development. The first-in-class Fdrug is evolved from Biotecnol’s

Cardioxane is an oncology support drug that prevents chronic cumulative cardiotoxicity caused by high dose anthracycline chemotherapy. In 1992, it was licensed for international markets but its label

Lebrikizumab is a novel and humanized monoclonal antibody designed to specifically block the action of IL-13, a cytokine that is a central pathogenic mediator in atopic dermatitis. Roche

The acquisition, expands the Group’s presence within the US healthcare market and increases US sales by more than double, bringing together two highly complementary technology and product platforms

The Neurological Clinical Research Institute (NCRI) at the Massachusetts General Hospital (MGH) and the Northeast ALS Consortium (NEALS) will oversee the trial, and 25 NEALS member medical centers

ECD is a rare, serious blood disease characterized by the abnormal multiplication of certain white blood cells called histiocytes. Zelboraf was also granted Breakthrough Therapy Designation (BTD) by

This is in addition to the existing MIA (IMP) licence for Investigational Medicinal Products (IMPs) manufacture, which the Group has held for over 10 years. Including significant know-how